AbbVie Stock: Keep Calm And Buy The Dip

Group 1 - AbbVie shares are experiencing a significant decline of nearly 10% following the failure of its schizophrenia treatment drug to meet its primary endpoint in a late-stage study [1] - The failure of the drug represents a substantial setback for AbbVie, impacting investor confidence and market perception [1] Group 2 - The article does not provide additional insights or data regarding the broader industry context or other companies [2]